Arsenic trioxide is an immune adjuvant in liver cancer treatment

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Tumor cells are effectively inhibited by arsenic trioxide (As2O3) in vitro and in vivo.
• The precise immune regulatory mechanisms underlying As2O3's anti-tumor effects are not fully understood.
• Regulatory T cells (Tregs) are known to play a critical role in tumor immune escape.

Purpose of the Study:

• To investigate the in vivo effects of As2O3 on the immune status in hepatic cancer.
• To assess the in vitro regulatory role of As2O3 in cytokine-induced killer (CIK) cell cytotoxicity.

Main Methods:

• Utilized a H22 xenograft model of hepatic cancer in vivo.
• Administered As2O3 treatment to assess effects on tumor volume, weight, survival, and immune cell infiltration (Tregs, CD3+ T lymphocytes).
• Evaluated As2O3's in vitro effects on CIK cell cytotoxicity, CD4+ T lymphocytes, CD8+ T lymphocytes, and Tregs.

Main Results:

• As2O3 treatment significantly decreased tumor volumes and weights, and improved survival in the hepatic cancer model.
• As2O3 reduced Treg infiltration into the tumor and increased CD3+ T lymphocyte amounts.
• In vitro, As2O3 enhanced CIK cell cytotoxicity by decreasing CD4+ T lymphocytes and Tregs, while increasing CD8+ T lymphocytes.

Conclusions:

• As2O3 demonstrates potential as an immune adjuvant in liver carcinoma treatment.
• As2O3 enhances anti-tumor immunity by modulating T lymphocyte populations and reducing Treg infiltration.
• The findings suggest As2O3 could be a valuable therapeutic agent for hepatic cancer by boosting the host's immune response.